---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-015315"
form_type: "8-K"
ticker: "OBIO"
cik: "0001814114"
company_name: "Orchestra BioMed Holdings, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:48:43.691591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.

## Summary
- CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.
- President/COO Mark Sherman base salary raised 10%; target bonus increased from 80% to 90% of base.
- 2026 bonus plan ties to clinical trial enrollment milestones for BACKBEAT and Virtue SAB studies.
- RSU awards now vest 25% at 18, 24, 30, and 36 months; prior schedule changed.
- CFO Andrew Taylor's bonus can be adjusted -45% to +0% based on individual performance objectives.

## SEC filing metadata
- accession: 0001104659-26-015315
- form_type: 8-K
- ticker: OBIO
- cik: 0001814114
- company_name: Orchestra BioMed Holdings, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/0001104659-26-015315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/tm266305d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-015315
- JSON: https://secwatch.observer/filing/0001104659-26-015315.json
- Plain text: https://secwatch.observer/filing/0001104659-26-015315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.